XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.25.1

Stockholders’ Deficiency (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Stockholders’ Deficiency [Abstract] |
Schedule of Activity for the Warrants | The schedule of activity for the warrants is as follows:
|  | Number of Warrants |  |  | Weighted Average Exercise Price (as converted) |  |  | Remaining Contractual Term (Years) |
Balance, December 31, 2024 |  |  | 3,635,962 |  |  | $ | 7.37 |  |  |  | 3.30 |
Balance, March 31, 2025 |  |  | 3,635,962 |  |  | $ | 7.37 |  |  |  | 3.05 |
Schedule of Warrants Outstanding and Exercisable | A summary of the warrants outstanding and exercisable as of March 31, 2025, is as follows:
Warrants Outstanding |  |  | Exercise Price |  |  | Expiry Date
| 133,193 |  |  | $ | 7.75 |  |  | August 31, 2026
| 35,064 |  |  | $ | 7.75 |  |  | October 16, 2026
| 101,000 |  |  | $ | 7.75 |  |  | November 8, 2026
| 394,572 |  |  | $ | 7.75 |  |  | December 22, 2026
| 720,123 |  |  | $ | 7.75 |  |  | January 19, 2027
| 585,609 |  |  | $ | 7.23 |  |  | February 16, 2028
| 86,200 |  |  | $ | 6.78 (CAD$9.75 | ) |  | February 16, 2028
| 28,796 |  |  | $ | 6.78 (CAD$9.75 | ) |  | March 15, 2028
| 262,287 |  |  | $ | 7.08 |  |  | March 15, 2028
| 430,805 |  |  | $ | 7.19 |  |  | September 24, 2029
| 642,892 |  |  | $ | 7.18 |  |  | November 8, 2029
| 215,421 |  |  | $ | 7.19 |  |  | November 13, 2029
| 3,635,962 |  |  |  |  |  |  |
A summary of warrants not issued for services with CAD exercise prices outstanding and exercisable as of March 31, 2025, is as follows:
Warrants Outstanding |  |  | Exercise Price |  |  | Expiry Date
| 86,200 |  |  | $ | 6.78 (CAD$9.75 | ) |  | February 16, 2028
| 15,810 |  |  | $ | 6.78 (CAD$9.75 | ) |  | March 15, 2028
| 102,010 |  |  |  |  |  |  |
A summary of the Initial and Additional Debenture Warrants issued and outstanding as of March 31, 2025, is as follows:
Warrants Outstanding |  |  | Exercise Price |  |  | Expiry Date
| 430,805 |  |  | $ | 7.19 |  |  | September 24, 2029
| 215,421 |  |  | $ | 7.19 |  |  | November 13, 2029
| 646,226 |  |  |  |  |  |  |
A summary of the agent warrants issued and outstanding as of March 31, 2025, is as follows:
Warrants Outstanding |  |  | Exercise Price |  |  | Expiry Date
| 642,892 |  |  | $ | 7.18 |  |  | November 9, 2029
Schedule of Derivative Liability | As of March 31, 2025 and December 31, 2024, the Company revalued the derivative liability to $415,434 and $503,129, respectively, and recorded a gain on revaluation of $87,695 for the three months ended March 31, 2025 (three months ended March 31, 2024 – loss of $619,989).
Balance as of December 31, 2024 |  | $ | 503,129 |
Revaluation of derivative liability |  |  | (87,695 | )
Balance as of March 31, 2025 |  | $ | 415,434 |
Schedule of Weighted Average Assumptions were used in the Black-Scholes Option-Pricing Model | The following weighted average assumptions were used in the Black-Scholes option-pricing model for the re-valuations as of March 31, 2025 and December 31, 2024:
|  | March 31, 2025 |  |  | December 31, 2024 |
Risk-free interest rate |  |  | 4.27 | % |  |  | 4.27 | %
Dividend yield |  |  | - |  |  |  | - |
Expected life (in years) |  |  | 2.89 |  |  |  | 3.14 |
Volatility |  |  | 158 | % |  |  | 158 | %
Weighted average fair value per warrant |  | $ | 4.07 |  |  | $ | 4.93 |
The following weighted average assumptions were used in the Black-Scholes option-pricing model for the revaluation for the Initial and Additional Debenture Warrant as of December 31, 2024 and March 31, 2025:
|  | March 31, 2025 |  |  | December 31, 2024 |
Risk-free interest rate |  |  | 3.96 | % |  |  | 4.38 | %
Dividend yield |  |  | - |  |  |  | - |
Expected life (in years) |  |  | 4.53 |  |  |  | 4.73 |
Volatility |  |  | 93 | % |  |  | 94 | %
The following weighted average assumptions were used in the Black-Scholes option-pricing model for the revaluations:
|  | March 31, 2025 |  |  | December 31, 2024 |
Risk-free interest rate |  |  | 3.96 | % |  |  | 4.38 | %
Dividend yield |  |  | - |  |  |  | - |
Expected life (in years) |  |  | 4.61 |  |  |  | 4.86 |
Volatility |  |  | 94 | % |  |  | 95 | %
The following weighted average assumptions were used in the Black-Scholes option-pricing model for the valuation of the Common Share options issued:
|  | March 31, 2025 |  |  | December 31, 2024 |
Risk-free interest rate |  |  | 4.31 | % |  |  | 4.34 | %
Expected life (in years) |  |  | 10 |  |  |  | 10 |
Volatility |  |  | 82 | % |  |  | 82 | %
Weighted average fair value per option |  | $ | 4.91 |  |  | $ | 5.58 |
Schedule of Share-Based Compensation Expense | The following table summarizes the total amount of share-based compensation expense related to service conditions for Common Share options during the three months ended March 31, 2025, and 2024:
|  | For the Three Months Ended |
|  | March 31, 2025 |  |  | March 31, 2024 |
Research and development |  | $ | 33,079 |  |  | $ | 87,847 |
General and administrative |  |  | 1,322,294 |  |  |  | 260,238 |
Total share-based compensation |  | $ | 1,355,373 |  |  | $ | 348,085 |
Schedule of Common Share Option Activity | Common share option activity is as follows:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Value(1) |
Balance, December 31, 2024 |  |  | 888,529 |  |  | $ | 4.58 |  |  |  | 8.36 |  |  | $ | 1,159,843 |
Granted |  |  | 1,165,522 |  |  |  | 5.93 |  |  |  |  |  |  |  |  |
Balance, March 31, 2025 |  |  | 2,054,121 |  |  |  | 5.32 |  |  |  | 8.80 |  |  |  | 725,617 |
Options exercisable, March 31, 2025 |  |  | 746,240 |  |  | $ | 4.50 |  |  |  | 7.20 |  |  | $ | 563,504 |
(1) | The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share. The calculation excludes options with an exercise price higher than the closing price of the Company’s share on the reporting date.
The following table summarizes ACI Canada legacy performance option activity for the Company:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Aggregate Intrinsic Value(1) |
Balance, December 31, 2024 |  |  | 265,642 |  |  |  | 0.22 |  |  |  | 3.48 |  |  |  | 1,506,321 |
Balance, March 31, 2025 |  |  | 265,642 |  |  |  | 0.22 |  |  |  | 3.23 |  |  |  | 1,285,838 |
Options exercisable, March 31, 2025 |  |  | 258,362 |  |  | $ | 0.22 |  |  |  | 3.21 |  |  | $ | 1,250,821 |
(1) | The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share. The calculation excludes options with an exercise price higher than the closing price of the Company’s shares on the reporting date
Schedule of Common Share Options Outstanding | A summary of the Common Share options outstanding at March 31, 2025, is as follows:
Options Outstanding |  |  | Options Exercisable |  |  | Exercise Price |  |  | Expiry Date
| 7,300 |  |  |  | 7,300 |  |  |  | 4.87 | (CAD$7.00 | ) |  | September 30, 2025
| 82,367 |  |  |  | 82,367 |  |  |  | 3.83 | (CAD$5.50 | ) |  | September 30, 2025
| 1,566 |  |  |  | 1,566 |  |  | $ | 10.00 |  |  |  | June 1, 2029
| 1,566 |  |  |  | 1,566 |  |  | $ | 10.00 |  |  |  | July 22, 2030
| 104,000 |  |  |  | 104,000 |  |  | $ | 4.87 | (CAD$7.00 | ) |  | August 3, 2031
| 37,600 |  |  |  | 37,600 |  |  | $ | 4.87 | (CAD$7.00 | ) |  | December 20, 2031
| 8,600 |  |  |  | 8,600 |  |  | $ | 4.87 | (CAD$7.00 | ) |  | February 14, 2032
| 18,000 |  |  |  | 18,000 |  |  | $ | 4.87 | (CAD$7.00 | ) |  | May 31, 2032
| 477,600 |  |  |  | 347,006 |  |  | $ | 3.83 | (CAD$5.50 | ) |  | June 8, 2033
| 32,000 |  |  |  | 2,667 |  |  | $ | 10.43 | (CAD$15.00 | ) |  | October 21, 2034
| 84,000 |  |  |  | 7,001 |  |  | $ | 5.70 | (CAD$8.20 | ) |  | November 26, 2034
| 34,000 |  |  |  | 2,834 |  |  | $ | 5.03 |  |  |  | December 24, 2034
| 10,000 |  |  |  | - |  |  |  | 6.00 |  |  |  | January 14, 2035
| 52,500 |  |  |  | - |  |  |  | 5.80 |  |  |  | February 12, 2035
| 1,005,822 |  |  |  | 125,732 |  |  |  | 5.93 |  |  |  | February 25, 2035
| 8,000 |  |  |  | - |  |  |  | 5.75 |  |  |  | March 4, 2035
| 89,200 |  |  |  | - |  |  |  | 5.55 |  |  |  | March 20, 2035
| 2,054,121 |  |  |  | 746,240 |  |  |  |  |  |  |
Schedule of Canada Legacy Performance Options Outstanding | A summary of the ACI Canada legacy performance options outstanding at March 31, 2025, is as follows:
Options Outstanding |  |  | Options Exercisable |  |  | Exercise Price |  |  | Expiry Date
| 36,000 |  |  |  | 36,000 |  |  | $ | 0.025 |  |  | February 1, 2026
| 27,642 |  |  |  | 27,642 |  |  | $ | 0.25 |  |  | December 31, 2027
| 122,000 |  |  |  | 121,120 |  |  | $ | 0.25 |  |  | September 1, 2028
| 80,000 |  |  |  | 73,600 |  |  | $ | 0.25 |  |  | June 1, 2029
| 265,642 |  |  |  | 258,362 |  |  |  |  |  |  |

X
- Definition Tabular disclosure of activity for the warrants. + References No definition available. + Details
Name: | acog_ScheduleOfActivityForTheWarrantsTableTextBlock
Namespace Prefix: | acog_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of Canada Legacy Performance Options Outstanding. + References No definition available. + Details
Name: | acog_ScheduleOfCanadaLegacyPerformanceOptionsOutstandingTableTextBlock
Namespace Prefix: | acog_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration